A Study of LY3200882 in Participants With Solid Tumors
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
223estimated
Sites
18
Countries
Australia, Canada, France +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2016-11-21 | actual | When the study began enrolling |
| Primary completion | 2020-02-27 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2016-10-18 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Solid Tumor
Interventions
- Drug: LY3200882
- Drug: LY3300054
- Drug: Gemcitabine
- Drug: nab-Paclitaxel
- Drug: Cisplatin
- Radiation: Intensity Modulated Radiotherapy
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants Who Experienced Dose-Limiting Toxicities (DLTs)
measured Cycle 1 (28 days)
Part B: Overall Response Rate (ORR): Percentage of Participants with Complete Response (CR) or Partial Response (PR)
measured Baseline through Disease Progression or Death (estimated at up to 12 months)
Publications
- PMID 34548321 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed